Discover how the next generation of DMTA is creating a future-ready drug discovery engine through AI and automation.
insights from industryBernd GleixnerDivision President AutomationBruker Biopsin News Medical speaks to Bernd Gleixner, Division President Automation at Bruker Biospin, about the future of lab ...
DeepMind has shared the discovery of 2.2 million new crystals – equivalent to nearly 800 years’ worth of knowledge. They introduce Graph Networks for Materials Exploration (GNoME), a new deep learning ...
Automated laboratories can streamline synthetic approaches and molecular discovery at unprecedented levels. As technology improves, one must consider how best to automate the laboratory and train the ...
Pharmaceutical R&D and quality control face increasing demands for speed, scalability, and regulatory compliance – yet many workflows remain manual, fragmented, and resource-intensive. In this webinar ...
With over 150,000 new materials developed by the Materials Project computers, Berkeley Lab, headquartered in California, could not synthesize these novel materials quickly enough to evaluate them for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results